A group from University of South Florida, Morsani College of Medicine, USA, etc. has reported 50-gene risk profiles in peripheral blood associated with COVID-19 disease severity.
In high risk groups, 7 genes were up-regulated (PLBD1, TPST1, MCEMP1, IL1R2, HP, FLT3, S100A12), and 43 genes were down-regulated (LCK, CAMK2D, NUP43, SLAMF7, LRRC39, ICOS, CD47, LBH, SH2D1A, CNOT6L, METTL8, ETS1, P2RY10, TRAT1, BTN3A1, LARP4, TC2N, GPR183, MORC4, STAT4, LPAR6, CPED1, DOCK10, ARHGAP5, HLA-DPA1, BIRC3, GPR174, CD28, UTRN, CD2, HLA-DPB1, ARL4C, BTN3A3, CXCR6, DYNC2LI1, BTN3A2, ITK, CD96, GBP4, S1PR1, NAP1L2, KLF12, IL7R).
A list of 50-gene expressing cells are summarized in a Table below. This table provides evidence of the cellular source of 50-gene expression changes in peripheral blood and point at specific cell types potentially associated with increased risk of mortality in COVID-19. It is shown that the increased proportion of CD4+ and CD8+ T lymphocytes and immunoglobulin-producing plasmablasts are related to low-risk groups, suggesting that a strong T cell response is associated with better disease outcomes.